{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/insomnia/prescribing-information/melatonin/","result":{"pageContext":{"chapter":{"id":"c581c21d-a147-50d8-8437-df289bb720bf","slug":"melatonin","fullItemName":"Melatonin","depth":2,"htmlHeader":"<!-- begin field 4d546ed0-b436-4288-89a5-14752fed6a62 --><h2>What issues should I be aware of when prescribing modified released melatonin?</h2><!-- end field 4d546ed0-b436-4288-89a5-14752fed6a62 -->","summary":"","htmlStringContent":"<!-- begin item 1427a266-bdb0-42b4-b637-6812fca16da7 --><!-- begin field c8ec773b-9a17-4ccb-89f2-cd06af4feb82 --><p>Be aware that recent data suggest similar safety concerns with melatonin to those associated with other hypnotic drugs (falls, accidents, cognitive impairment, dependence and withdrawal symptoms, and an increased risk of dementia) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]. </p><h3>Indications and dose</h3><ul><li>The recommended oral dose of modified-release melatonin for insomnia (short-term use only) for an adult aged 55 years and over is 2 mg once daily (1–2 hours before bedtime and after food) for up to 13 weeks.<ul><li>The recommended initial duration of treatment is 3 weeks continued if there is a response to treatment for a further 10 weeks only.</li></ul></li></ul><h3>Contraindications and cautions</h3><ul><li>Melatonin should be avoided in:<ul><li>Hepatic impairment.</li><li>Autoimmune disease — no clinical data available.</li><li>Pregnancy, breastfeeding and in women planning a pregnancy.</li></ul></li><li>Use melatonin with caution in:<ul><li>Renal impairment — no information available.</li><li>The elderly — has been associated with falls.</li></ul></li></ul><h3>Adverse effects</h3><ul><li>The adverse effects of melatonin include:<ul><li>Arthralgia, headache, increased risk of infection, abdominal pain, dyspepsia, dry mouth, mouth ulceration, nausea, weight gain, hypertension, chest pain, malaise, dizziness, restlessness, nervousness, irritability, anxiety, abnormal dreams, proteinuria, glycosuria, pruritus, rash, and dry skin.</li><li>Drowsiness — moderate influence on ability to drive and use machines.</li></ul></li></ul><h3>Drug interactions</h3><ul><li>Drug interactions of modified-release melatonin include:<ul><li>Alcohol, opioids and other drugs with CNS depressant effects —can affect ability to perform skilled tasks.</li><li>Fluvoxamine — fluvoxamine markedly increases melatonin levels by inhibiting its metabolism by hepatic cytochrome P450; avoid concomitant use.</li><li>Quinolones — quinolones are thought to increase melatonin levels; manufacturer advises caution.</li><li>Combined hormonal contraceptives are thought to increase exposure to melatonin; manufacturer advises caution.</li><li>Warfarin — case reports suggest that melatonin may either increase or decrease the international normalised ratio (INR). If used concurrently consider increasing frequency of INR monitoring.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]</p><!-- end field c8ec773b-9a17-4ccb-89f2-cd06af4feb82 --><!-- end item 1427a266-bdb0-42b4-b637-6812fca16da7 -->","topic":{"id":"d32ed400-7d0f-58c1-b35a-07cabeb7198f","topicId":"c95c9c90-991c-42bf-9bb6-260f08eb9d32","topicName":"Insomnia","slug":"insomnia","lastRevised":"Last revised in January 2020","chapters":[{"id":"99b2443e-da9c-5c9d-8066-cea961d77010","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"775bdb91-759e-5182-aa24-3faa2be61175","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4b1bac5b-de37-521d-afa3-7222f1f8a344","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"079ebee9-04a4-5115-ad9d-4ec64285cafe","slug":"changes","fullItemName":"Changes"},{"id":"fadd9470-736e-56b5-9e47-fabc4c25c40a","slug":"update","fullItemName":"Update"}]},{"id":"6d4dc1da-3cad-586f-9720-807538e37ae0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd70908f-732c-56f4-96ee-63c1a0d48b93","slug":"goals","fullItemName":"Goals"},{"id":"7c916994-5730-5df1-a42d-0903da669227","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3babc745-3146-54d7-a591-229458269920","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c9a1ae6b-b43f-5001-9ce6-eec4fe6a51d6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"782e1bf0-98b1-5461-be78-dcabc4e8768b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bf1c4d94-7a24-5b6b-b08e-2e91d584da67","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f99b4301-f0d0-5b2d-9c5d-5448b2c5ae71","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e829a9d8-9a8a-5fff-acc0-b36a76b06365","slug":"definition","fullItemName":"Definition"},{"id":"71bd7cfa-09cb-59bc-8596-cf8b380bdfc8","slug":"causes","fullItemName":"Causes"},{"id":"d3f6ead4-def6-5d80-82da-6a216bbf5205","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a96dbcb1-2be5-5896-958a-015d9d9ff705","slug":"prognosis","fullItemName":"Prognosis"},{"id":"d70599ab-d67b-56eb-a550-5eb50783af51","slug":"complications","fullItemName":"Complications"}]},{"id":"908b4222-ad0d-5cb4-b245-b6613b9935af","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1ef90db4-827f-5f00-89c3-71b0b81deeed","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"db78ccd5-ae24-5f11-9afb-47d56a4e8c1a","slug":"assessment","fullItemName":"Assessment"},{"id":"e1f82dba-1dd1-5cd6-89fd-df0bb7eea4b2","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b989149-2d7c-55da-a785-3b93e4e9e30d","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d6f6f9c-bb55-5871-81f4-30b4b0e1e3ce","slug":"managing-short-term-insomnia-less-3-months","fullItemName":"Scenario: Managing short-term insomnia (< 3 months)"},{"id":"9c9c0f54-a495-58d5-9a6f-00b3ea587356","slug":"managing-long-term-insomnia-greater-3-months","fullItemName":"Scenario: Managing long-term insomnia (> 3 months)"}]},{"id":"d5ba983f-3e5f-57df-9f8b-dcf81a11b4e9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"34ae23e7-59a3-54c1-80f6-944b0b43d4c4","slug":"z-drugs","fullItemName":"Z-drugs"},{"id":"c581c21d-a147-50d8-8437-df289bb720bf","slug":"melatonin","fullItemName":"Melatonin"}]},{"id":"787787e5-4b3f-5665-bb53-35fba2334669","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"248c0d90-0e6b-5fc7-b6ab-94f0aca25c78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"964993b0-a6a2-584e-b2b2-1d307e45d4a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fc22a18-8f09-58a9-aaf9-e4d181a88b4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3eed36c6-8b0c-5776-aa33-aba8181960d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e9c29199-597b-5045-bb8e-91f46f5641cc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"54861215-5c9f-5992-83e2-44e0d123cd39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40987924-ac87-5c7f-8d13-d6233cd2729a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d5ba983f-3e5f-57df-9f8b-dcf81a11b4e9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}